Another damning report by an Indian parliamentary panel on clinical trials, this time with scathing comments against the US-based non-profit organization PATH over the conduct of studies concerning human papillomavirus (HPV) vaccines, could potentially have serious implications for Merck & Co's Gardasil and GlaxoSmithKline's Cervarix vaccines in the country1.
Another damning report by an Indian parliamentary panel on clinical trials, this time with scathing comments against the US-based non-profit organization PATH over the conduct of studies concerning human papillomavirus (HPV) vaccines, could potentially have serious implications for Merck & Co's Gardasil and GlaxoSmithKline's Cervarix vaccines in the country1.
The parliamentary panel report also has some strong words against the Indian Council of Medical Research and the Drugs Controller...
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.
